| Symbol | SPRC |
|---|---|
| Name | SCISPARC LTD. |
| Sector | HEALTH CARE |
| Region | Middle East |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 20 RAUL WALLENBERG STREET,TOWER A, 2ND FLOOR, TEL AVIV, 6971916, Israel |
| Telephone | +972 37175777 |
| Fax | — |
| — | |
| Website | https://www.scisparc.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001611746 |
| Description | SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company operates in the single segment of the Development of drugs based on cannabinoid molecules to be approved by an official regulatory authority. Additional info from NASDAQ: |
SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination
Read moreSciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome
Read moreSciSparc: Subsidiary NeuroThera Labs Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics
Read moreSciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company
Read moreSciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity
Read more